American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2001.
Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension: a review. Hypertension.1989;13:I36-I44.
Psaty BM, Smith NL, Siscovick DS.
et al. Health outcomes associated with antihypertensive therapies used as
first-line agents: a systematic review and meta-analysis. JAMA.1997;277:739-745.
Not Available. The sixth report of the Joint National Committee on prevention, detection,
evaluation, and treatment of high blood pressure. Arch Intern Med.1997;157:2413-2446.
Chalmers J, Zanchetti A. The 1996 report of a World Health Organization expert committee on
hypertension control. J Hypertens.1996;14:929-933.
Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. Lancet.1990;336:370-371.
World Health Organization-International Society of Hypertension Blood
Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized
trials of blood pressure lowering treatments. J Hypertens.1998;16:127-137.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons
with isolated systolic hypertension: final results of the Systolic Hypertension
in the Elderly Program (SHEP). JAMA.1991;265:3255-3264.
Staessen JA, Fagard R, Thijs L.
et al. Randomised double-blind comparison of placebo and active treatment
for older patients with isolated systolic hypertension: the Systolic Hypertension
in Europe (Syst-Eur) Trial Investigators. Lancet.1997;350:757-764.
Yusuf S, Sleight P, Pogue J.
et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on
cardiovascular events in high-risk patients: the Heart Outcomes Prevention
Evaluation Study Investigators. N Engl J Med.2000;342:145-153.
PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen
among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet.2001;358:1033-1041.
Grimm Jr RH. Antihypertensive therapy: taking lipids into consideration. Am Heart J.1991;122:910-918.
Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering
drugs: results of prospectively designed overviews of randomised trials: Blood
Pressure Lowering Treatment Trialists' Collaboration. Lancet.2000;356:1955-1964.
Pahor M, Psaty BM, Alderman MH.
et al. Health outcomes associated with calcium antagonists compared with other
first-line antihypertensive therapies: a meta-analysis of randomised controlled
Poulter NR. Treatment of hypertension: a clinical epidemiologist's view. J Cardiovasc Pharmacol.1991;18(suppl 2):S35-S38.
Neaton JD, Grimm Jr RH, Prineas RJ.
et al. Treatment of mild hypertension study: final results: Treatment of Mild
Hypertension Study Research Group. JAMA.1993;270:713-724.
Materson BJ, Reda DJ, Cushman WC.
et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive
agents with placebo: the Department of Veterans Affairs Cooperative Study
Group on Antihypertensive Agents. N Engl J Med.1993;328:914-921.
Davis BR, Cutler JA, Gordon DJ.
et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens.1996;9:342-360.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research
Group. Major cardiovascular events in hypertensive patients randomized to
doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT). JAMA.2000;283:1967-1975.
Davis BR, Cutler JA, Furberg CD.
et al. Relationship of antihypertensive treatment regimens and change in blood
pressure to risk for heart failure in hypertensive patients randomly assigned
to doxazosin or chlorthalidone: further analyses from the Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Ann Intern Med.2002;137:313-320.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research
Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients
randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial. JAMA.2002;288:2998-3007.
Grimm Jr RH, Margolis KL, Papademetriou V.
et al. Baseline characteristics of participants in the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension.2001;37:19-27.
Not Available. The fifth report of the Joint National Committee on Detection, Evaluation,
and Treatment of High Blood Pressure (JNC V). Arch Intern Med.1993;153:154-183.
Levey AS, Bosch JP, Lewis JB.
et al. A more accurate method to estimate glomerular filtration rate from
serum creatinine: a new prediction equation: Modification of Diet in Renal
Disease Study Group. Ann Intern Med.1999;130:461-470.
Levey AS, Greene T, Kusek JW.
et al. A simplified equation to predict glomerular filtration rate from serum
creatinine. J Am Soc Nephrol.2000;11:155A.
Piller LB, Davis BR, Cutler JA.
et al. Validation of heart failure events in ALLHAT participants assigned
to doxazosin. Curr Control Trials Cardiovasc Med.2002;3:10.
Public Health Service-Health Care Financing Administration. International Classification of Diseases, Ninth Revision
(ICD-9). 6th ed. Bethesda, Md: US Dept of Health and Human Services; 2001.
DHHS Publication No. (PHS) 80-1260.
Dunnett CW. A multiple comparisons procedure for comparing several treatments with
a control. J Am Stat Assoc.1955;50:1096-1121.
Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated
Regression. New York, NY: Springer-Verlag; 1997.
Davis BR, Hardy RJ. Upper bounds for type I and II error rates in conditional power calculations. Commun Stat.1990;19:3571-3584.
Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika.1983;70:659-663.
Hansson L, Lindholm LH, Ekbom T.
et al. Randomised trial of old and new antihypertensive drugs in elderly patients:
cardiovascular mortality and morbidity: the Swedish Trial in Old Patients
with Hypertension-2 study. Lancet.1999;354:1751-1756.
Brown MJ, Palmer CR, Castaigne A.
et al. Morbidity and mortality in patients randomised to double-blind treatment
with a long-acting calcium-channel blocker or diuretic in the International
Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet.2000;356:366-372.
MacMahon S, Neal B. Differences between blood-pressure-lowering drugs. Lancet.2000;356:352-353.
Kostis JB, Davis BR, Cutler J.
et al. Prevention of heart failure by antihypertensive drug treatment in older
persons with isolated systolic hypertension: SHEP Cooperative Research Group. JAMA.1997;278:212-216.
Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation
and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease,
cancer and bleeding. J Hypertens.1997;15:105-115.
Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary
heart disease. Circulation.1995;92:1326-1331.
Agodoa LY, Appel L, Bakris GL.
et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive
nephrosclerosis: a randomized controlled trial. JAMA.2001;285:2719-2728.
Hall WD, Kusek JW, Kirk KA.
et al. Short-term effects of blood pressure control and antihypertensive drug
regimen on glomerular filtration rate: the African-American Study of Kidney
Disease and Hypertension Pilot Study. Am J Kidney Dis.1997;29:720-728.
ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression
of nondiabetic chronic renal disease. Arch Intern Med.1994;154:1185-1202.
Lonn EM, Yusuf S, Jha P.
et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac
and vascular protection. Circulation.1994;90:2056-2069.
Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension
management. Am J Hypertens.1999;12:205S-213S.
Jafar TH, Schmid CH, Landa M.
et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic
renal disease: a meta-analysis of patient-level data. Ann Intern Med.2001;135:73-87.
Not Available. Effect of enalapril on mortality and the development of heart failure
in asymptomatic patients with reduced left ventricular ejection fractions:
the SOLVD Investigators. N Engl J Med.1992;327:685-691.
Collins R, Peto R, MacMahon S.
et al. Blood pressure, stroke, and coronary heart disease: Part 2, short-term
reductions in blood pressure: overview of randomised drug trials in their
epidemiological context. Lancet.1990;335:827-838.
MacMahon S, Peto R, Cutler J.
et al. Blood pressure, stroke, and coronary heart disease: Part 1, prolonged
differences in blood pressure: prospective observational studies corrected
for the regression dilution bias. Lancet.1990;335:765-774.
Staessen JA, Byttebier G, Buntinx F.
et al. Antihypertensive treatment based on conventional or ambulatory blood
pressure measurement: a randomized controlled trial: Ambulatory Blood Pressure
Monitoring and Treatment of Hypertension Investigators. JAMA.1997;278:1065-1072.
Franklin SS. Cardiovascular risks related to increased diastolic, systolic and pulse
pressure: an epidemiologist's point of view. Pathol Biol (Paris).1999;47:594-603.
Saunders E, Weir MR, Kong BW.
et al. A comparison of the efficacy and safety of a beta-blocker, a calcium
channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med.1990;150:1707-1713.
Rahman M, Douglas JG, Wright JT. Pathophysiology and treatment implications of hypertension in the African-American
population. Endocrinol Metab Clin North Am.1997;26:125-144.
Cushman WC, Reda DJ, Perry HM.
et al. Regional and racial differences in response to antihypertensive medication
use in a randomized controlled trial of men with hypertension in the United
States. Arch Intern Med.2000;160:825-831.
Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy
in black as compared with white patients with left ventricular dysfunction. N Engl J Med.2001;344:1351-1357.
Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis
of the vasodilator-heart failure trials: Vasodilator-Heart Failure Trial Study
Group. J Card Fail.1999;5:178-187.
Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression
from asymptomatic left ventricular dysfunction to symptomatic heart failure
in black and white patients. J Am Coll Cardiol.2002;40:311-317.
Manolio TA, Cutler JA, Furberg CD.
et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med.1995;155:829-837.